Population pharmacokinetics of the BEACOPP polychemotherapy regimen in Hodgkin's lymphoma and its effect on myelotoxicity
- PMID: 17375983
- DOI: 10.2165/00003088-200746040-00005
Population pharmacokinetics of the BEACOPP polychemotherapy regimen in Hodgkin's lymphoma and its effect on myelotoxicity
Abstract
Background and objective: The BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone) chemotherapy regimen for the treatment of advanced Hodgkin's lymphoma has a superior outcome, but its toxicity (mainly haematotoxicity) is pronounced and highly variable. The present study was conducted to address the role of pharmacokinetics in individual toxicity.
Study design: Three plasma samples and a 24-hour urine collection for day 1 of the first three cycles of chemotherapy were analysed in 30 patients, and the pharmacokinetic parameters of the respective drugs were estimated by population pharmacokinetic methods (nonlinear mixed-effects model [NONMEM] software). Demographic data, doses and durations of infusion were also recorded. The effect of these parameters on platelet counts was estimated by analysis of covariance using a general linear model.
Results: The pharmacokinetic parameters and respective covariates were similar to the published data. The body surface area, peak concentrations of etoposide, urinary recovery of dechloroethylcyclophosphamide (formed by cytochrome P450 [CYP] 3A4) relative to the cyclophosphamide dose and number of cycles had a significant effect on toxicity. These factors explained 37% of the interindividual variability in the change in platelet counts from day 1 to day 8 of each cycle.
Conclusion: The results show that the individual pharmacokinetics of BEACOPP drugs are an important link between dosage and toxicity. Accordingly, individualisation of treatment based on pharmacokinetics may result in more uniform toxicity. Individualisation may also allow escalation of the mean dose, which is probably related to better efficacy. As a consequence of the present study, infusion rates should be standardised, and the potential of a dose reduction in the first cycle and of CYP3A4 phenotyping should be addressed in clinical studies.
Similar articles
-
14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.J Clin Oncol. 2003 May 1;21(9):1734-9. doi: 10.1200/JCO.2003.06.028. J Clin Oncol. 2003. PMID: 12721249 Clinical Trial.
-
BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.J Clin Oncol. 1998 Dec;16(12):3810-21. doi: 10.1200/JCO.1998.16.12.3810. J Clin Oncol. 1998. PMID: 9850026 Clinical Trial.
-
Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group (GHSG).Ann Oncol. 2000 Sep;11(9):1105-14. doi: 10.1023/a:1008301225839. Ann Oncol. 2000. PMID: 11061603 Clinical Trial.
-
BEACOPP: a new regimen for advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group.Ann Oncol. 1998;9 Suppl 5:S67-71. doi: 10.1093/annonc/9.suppl_5.s67. Ann Oncol. 1998. PMID: 9926240 Review.
-
Model based development of the BEACOPP regimen for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group.Ann Oncol. 1998;9 Suppl 5:S73-8. doi: 10.1093/annonc/9.suppl_5.s73. Ann Oncol. 1998. PMID: 9926241 Review.
Cited by
-
Effects of ranolazine in a model of doxorubicin-induced left ventricle diastolic dysfunction.Br J Pharmacol. 2017 Nov;174(21):3696-3712. doi: 10.1111/bph.13791. Epub 2017 May 16. Br J Pharmacol. 2017. PMID: 28320043 Free PMC article.
-
Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology.Clin Pharmacokinet. 2008;47(8):487-513. doi: 10.2165/00003088-200847080-00001. Clin Pharmacokinet. 2008. PMID: 18611060 Review.
-
Evaluation for pharmacokinetic exposure of cytotoxic anticancer drugs in elderly patients receiving (R-)CHOP therapy.Sci Rep. 2021 Jan 12;11(1):785. doi: 10.1038/s41598-020-80706-2. Sci Rep. 2021. PMID: 33436910 Free PMC article.
-
Fundamentals of population pharmacokinetic modelling: validation methods.Clin Pharmacokinet. 2012 Sep 1;51(9):573-90. doi: 10.1007/BF03261932. Clin Pharmacokinet. 2012. PMID: 22799590 Review.
-
Cytotoxic mechanisms of doxorubicin at clinically relevant concentrations in breast cancer cells.Cancer Chemother Pharmacol. 2022 Mar;89(3):285-311. doi: 10.1007/s00280-022-04400-y. Epub 2022 Feb 12. Cancer Chemother Pharmacol. 2022. PMID: 35150291 Review.
References
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Research Materials